Tiziana upbeat on latest Milciclib analysis

By

Sharecast News | 08 Dec, 2017

17:18 20/10/21

  • 58.50
  • 8.33%4.50
  • Max: 59.00
  • Min: 45.00
  • Volume: 272,736
  • MM 200 : 0.00

Clinical stage biotechnology company Tiziana Life Sciences announced on Friday that the independent data monitor committee (IDMC) has completed interim analysis of the safety and pharmacokinetic data from the first six patients in the Phase 2a trial of ‘Milciclib’.

Last news

Sunday newspaper round-up: Kursk, AstraZeneca, BAE Systems
US close: Major indices return some post-election gains
London close: Stocks end turbulent week in the red
Broker tips: Flutter Entertainment, Premier Foods
Director dealings: AstraZeneca CEO ups stake